A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis
References (0)
Cited by (117)
Identification of cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1
2020, Biochemical PharmacologyDesign, synthesis, biological evaluation and docking study of novel indole-2-amide as anti-inflammatory agents with dual inhibition of COX and 5-LOX
2019, European Journal of Medicinal ChemistryAGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis
2019, GastroenterologyCitation Excerpt :We identified 11 trials comparing different doses of mesalamine with each other or placebo for maintenance of remission, all of which enrolled patients in clinical and endoscopic remission, with or without histologic remission, for varying time periods of 6–12 months; outcome was reported as combined clinical and endoscopic remission based on validated disease activity indices. Standard-dose (2 RCTs, 510 patients; RR of failure to achieve remission, 0.55; 95% CI, 0.43–0.70)55,56 and low-dose (3 RCTs, 579 patients; RR, 0.63; 95% CI, 0.51–0.79)57–59 mesalamine were superior to placebo in maintaining remission in patients with mild–moderate UC (Supplementary Figure 4). With estimated placebo rates of maintenance of remission of 58%, 76.9%, and 73.5% patients treated with standard- and low-dose mesalamine maintained remission, respectively.
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses
2018, The Lancet Gastroenterology and HepatologyCitation Excerpt :One trial covered intervention for both induction and maintenance of remission, and was thus considered in both groups. We therefore included 48 randomised trials (8020 participants, including 1380 placebo-treated patients) comparing eight active interventions for induction of remission,23–70 and 28 randomised trials (4218 participants, including 575 placebo-treated patients) comparing six active interventions for maintenance of remission.23,71–97 The available direct comparisons and network of trials for induction and maintenance of clinical remission are shown in figure 2.
Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis
2016, European Journal of PharmacologyCitation Excerpt :Since the inhibition of one or both COX enzymes may shunt arachidonic acid metabolism to the 5-LOX pathway, zileuton, an active 5-lipoxygenase inhibitor, was compared in a trial versus mesalazine and placebo. However, zileuton was not superior to placebo in maintaining remission of symptoms in ulcerative colitis (Hawkey et al., 1997). Thus, it appears that a targeted inhibition of either COX or 5-LOX does not represent the proper therapeutic strategy to block the inflammatory response in IBDs.